Since ADAM10 and 17 upregulation results in the shedding of HER ligands and dimerization of HER2 with other HER receptors and their activation [22, 32], we investigated the effect of inhibiting HER receptors with the panHER inhibitor neratinib in combination with anti-HER2 agents (trastuzumab and pertuzumab) in HER2-low breast cancer cells. Here, ADAM10 is linked to breast cancer.